Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0IM6O
|
|||
| Former ID |
DIB008179
|
|||
| Drug Name |
Talactoferrin
|
|||
| Synonyms |
Talactoferrin (topical)
Click to Show/Hide
|
|||
| Indication | Diabetic foot ulcer [ICD-11: BD54; ICD-9: 707] | Phase 3 | [1] | |
| Company |
Agennix AG
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Lactotransferrin (LTF) | Target Info | Modulator | [2] |
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| Reactome | ROS production in response to bacteria | |||
| Amyloid formation | ||||
| WikiPathways | Latent infection of Homo sapiens with Mycobacterium tuberculosis | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00706862) Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. Am J Surg. 2007 Jan;193(1):49-54. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.